Premium
Internet‐assisted cognitive behavioral intervention for targeted therapy–related fatigue in chronic myeloid leukemia: Results from a pilot randomized trial
Author(s) -
Jim Heather S. L.,
Hyland Kelly A.,
Nelson Ashley M.,
PinillaIbarz Javier,
Sweet Kendra,
Gielissen Marieke,
Bulls Hailey,
Hoogland Aasha I.,
Jacobsen Paul B.,
Knoop Hans
Publication year - 2020
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.32521
Subject(s) - medicine , randomized controlled trial , quality of life (healthcare) , cognitive behavioral therapy , chronic fatigue , randomization , physical therapy , chronic fatigue syndrome , myeloid leukemia , nursing
Background Fatigue is a common and disabling side effect of targeted therapies such as tyrosine kinase inhibitors (TKIs) used to treat chronic myeloid leukemia (CML). The goal of the current study was to conduct a pilot randomized trial of the first cognitive behavioral intervention developed for fatigue due to targeted therapy. Methods Patients with CML treated with a TKI who were reporting moderate to severe fatigue were recruited and randomized 2:1 to cognitive behavioral therapy for targeted therapy–related fatigue (CBT‐TTF) delivered via FaceTime for the iPad or to a waitlist control (WLC) group. The outcomes were acceptability, feasibility, and preliminary efficacy for fatigue (Functional Assessment of Chronic Illness Therapy–Fatigue; primary outcome) and quality of life (Functional Assessment of Cancer Therapy–General; secondary outcome). Participants were assessed before randomization and after treatment (ie, approximately 18 weeks later). Results A total of 44 patients (mean age, 55 years; 48% female) were assigned to CBT‐TTF (n = 29) or WLC (n = 15). The study participation rate was 59%. Among the patients assigned to CBT‐TTF, 79% completed the intervention. Intent‐to‐treat analyses indicated that patients assigned to CBT‐TTF demonstrated greater improvements in fatigue ( d = 1.06; P < .001) and overall quality of life ( d = 1.15; P = .005) than those assigned to WLC. More patients randomized to CBT‐TTF than WLC demonstrated clinically significant improvements in fatigue (85% vs 29%) and quality of life (88% vs 54%; P values ≤ .016). Conclusions CBT‐TTF displays preliminary efficacy in improving fatigue and quality of life among fatigued patients with CML treated with TKIs. The findings suggest that a larger randomized study is warranted.